XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues:        
Research and development revenue $ 385,896 $ 837,159 $ 720,513 $ 1,815,211
Costs and expenses:        
Costs of research and development revenue 301,956 792,944 445,911 1,519,862
Research and development 515,629 917,552 1,038,352 1,728,118
General and administrative 1,607,756 1,402,569 3,396,350 2,882,609
Foreign currency exchange loss 3,146 14,521 8,049 25,543
Total costs and expenses 2,428,487 3,127,586 4,888,662 6,156,132
Loss from operations (2,042,591) (2,290,427) (4,168,149) (4,340,921)
Other income (expense):        
Interest income 138,471 109,194 225,914 213,925
Gain on sale of Alphazyme 0 28,273 60,977 1,017,592
Total other income (expense), net (2,632) 137,467 113,330 1,231,517
Net loss $ (2,045,223) $ (2,152,960) $ (4,054,819) $ (3,109,404)
Basic and diluted net loss per common share (in dollars per share) $ (0.07) $ (0.07) $ (0.14) $ (0.11)
Basic and diluted weighted-average common shares outstanding (in shares) 29,291,259 28,881,061 29,085,696 28,786,402
Nonrelated Party [Member]        
Other income (expense):        
Interest expense $ (88,634) $ 0 $ (110,273) $ 0
Related Party [Member]        
Other income (expense):        
Interest expense (52,469) 0 (63,288) 0
Research and Development [Member]        
Revenues:        
Research and development revenue 385,896 793,042 720,513 1,726,976
License [Member]        
Revenues:        
Research and development revenue $ 0 $ 44,117 $ 0 $ 88,235